筋萎縮(Muscle Atrophy):治療薬開発パイプライン動向(世界、2015年上半期版)

調査会社Global Markets Direct社が発行したリサーチレポート(データ管理コード:GMDHC6320IDB)
◆英語タイトル:Muscle Atrophy - Pipeline Review, H1 2015
◆発行会社/調査会社:Global Markets Direct
◆商品コード:GMDHC6320IDB
◆発行日:2015年2月10日
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆ページ数:42
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥678,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[筋萎縮(Muscle Atrophy):治療薬開発パイプライン動向(世界、2015年上半期版)]についてメールでお問い合わせはこちら
当調査レポートでは、世界における筋萎縮(Muscle Atrophy)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・筋萎縮(Muscle Atrophy)の概要
・筋萎縮(Muscle Atrophy)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・筋萎縮(Muscle Atrophy)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・筋萎縮(Muscle Atrophy)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・筋萎縮(Muscle Atrophy)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
*** レポート概要(サマリー)***

Muscle Atrophy – Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Muscle Atrophy – Pipeline Review, H1 2015’, provides an overview of the Muscle Atrophy’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Muscle Atrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Muscle Atrophy and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Muscle Atrophy
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Muscle Atrophy and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Muscle Atrophy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Muscle Atrophy pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Muscle Atrophy
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Muscle Atrophy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

*** レポート目次(コンテンツ)***

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Muscle Atrophy Overview 6
Therapeutics Development 7
Pipeline Products for Muscle Atrophy – Overview 7
Pipeline Products for Muscle Atrophy – Comparative Analysis 8
Muscle Atrophy – Therapeutics under Development by Companies 9
Muscle Atrophy – Therapeutics under Investigation by Universities/Institutes 10
Muscle Atrophy – Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Muscle Atrophy – Products under Development by Companies 13
Muscle Atrophy – Products under Investigation by Universities/Institutes 14
Muscle Atrophy – Companies Involved in Therapeutics Development 15
Acceleron Pharma, Inc. 15
Eli Lilly and Company 16
Fate Therapeutics, Inc. 17
Novartis AG 18
Rigel Pharmaceuticals, Inc. 19
Muscle Atrophy – Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
ACE-083 – Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Aptamer to Activate Calcineurin A for Genetic Disorders and Musculoskeletal Disorders – Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
bimagrumab – Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
LY-2495655 – Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Small Molecule for Muscle Atrophy – Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Small Molecule for Muscular Dystrophy and Other Muscle Disorders – Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Small Molecule to Inhibit Growth and Differentiation Factor 8 for Atrophy – Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Muscle Atrophy – Recent Pipeline Updates 38
Muscle Atrophy – Dormant Projects 40
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 41
Disclaimer 42

[List of Tables]
Number of Products under Development for Muscle Atrophy, H1 2015 7
Number of Products under Development for Muscle Atrophy - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Development, H1 2015 12
Products under Development by Companies, H1 2015 13
Products under Investigation by Universities/Institutes, H1 2015 14
Muscle Atrophy - Pipeline by Acceleron Pharma, Inc., H1 2015 15
Muscle Atrophy - Pipeline by Eli Lilly and Company, H1 2015 16
Muscle Atrophy - Pipeline by Fate Therapeutics, Inc., H1 2015 17
Muscle Atrophy - Pipeline by Novartis AG, H1 2015 18
Muscle Atrophy - Pipeline by Rigel Pharmaceuticals, Inc., H1 2015 19
Assessment by Monotherapy Products, H1 2015 20
Number of Products by Stage and Target, H1 2015 22
Number of Products by Stage and Mechanism of Action, H1 2015 24
Number of Products by Stage and Route of Administration, H1 2015 26
Number of Products by Stage and Molecule Type, H1 2015 28
Muscle Atrophy Therapeutics - Recent Pipeline Updates, H1 2015 38
Muscle Atrophy - Dormant Projects, H1 2015 40

[List of Figures]
Number of Products under Development for Muscle Atrophy, H1 2015 7
Number of Products under Development for Muscle Atrophy - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Products, H1 2015 12
Assessment by Monotherapy Products, H1 2015 20
Number of Products by Top 10 Targets, H1 2015 21
Number of Products by Stage and Top 10 Targets, H1 2015 22
Number of Products by Top 10 Mechanism of Actions, H1 2015 23
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 24
Number of Products by Top 10 Routes of Administration, H1 2015 25
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 26
Number of Products by Top 10 Molecule Types, H1 2015 27
Number of Products by Stage and Top 10 Molecule Types, H1 2015 28

*** 掲載企業 ***

Acceleron Pharma, Inc.
Eli Lilly and Company
Fate Therapeutics, Inc.
Novartis AG
Rigel Pharmaceuticals, Inc.

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(GMDHC6320IDB )"筋萎縮(Muscle Atrophy):治療薬開発パイプライン動向(世界、2015年上半期版)" (英文:Muscle Atrophy - Pipeline Review, H1 2015)はGlobal Markets Direct社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。